Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

New Products In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

J&J wins ceramic-on-metal hip approval

You may also be interested in...



Financings In Brief

Tria Beauty postpones IPO. Agendia raises $65 million for cancer tests. Kona Medical gets $30 million for hypertension device development. More financings.

FDA Orders Post-Market Studies On Metal-On-Metal Hips

FDA has ordered 21 current and former manufacturers of metal-on-metal total hip replacement systems to conduct post-market surveillance studies of their devices to assess metal toxicity risks.

J&J/DePuy's Ceramic-On-Metal Hip Is Approvable With Conditions - Panel

Johnson & Johnson/DePuy's CoMplete ceramic-on-metal acetabular hip system should be approved by FDA, according to the agency's Orthopedic and Rehabilitation Devices Panel

Table

View full table

Tags:
Latest Headlines

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

Mini-Slings Are Comparable To Traditional Ones To Treat Incontinence, FDA Says

Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

See All
UsernamePublicRestriction

Register

MT030268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By